Page last updated: 2024-11-05

1-hydroxy-2-naphthoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-Hydroxy-2-naphthoic acid, also known as 2-hydroxy-1-naphthoic acid, is a white crystalline organic compound. It is an important intermediate in the synthesis of various dyes, pharmaceuticals, and agrochemicals. The compound exhibits a wide range of biological activities including antibacterial, antifungal, anti-inflammatory, and anticancer properties. It is also used as a starting material for the production of other valuable chemicals. Extensive research has focused on its synthesis, applications, and pharmacological properties due to its potential in various fields.'

1-hydroxy-2-naphthoic acid: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1-hydroxy-2-naphthoic acid : A naphthoic acid with the carboxy group at position 2 and carrying a hydroxy substituent at the 1-position. It is a xenobiotic metabolite produced by the biodegradation of phenanthrene by microorganisms. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6844
CHEMBL ID229299
CHEBI ID36108
SCHEMBL ID25244
MeSH IDM0143427

Synonyms (63)

Synonym
AC-13237
CHEBI:36108 ,
F2191-0001
nsc-3717
nsc3717
2-carboxy-1-naphthol
1-hydroxy-2-naphthalenecarboxylic acid
2-naphthalenecarboxylic acid, 1-hydroxy-
2-naphthoic acid, 1-hydroxy-
inchi=1/c11h8o3/c12-10-8-4-2-1-3-7(8)5-6-9(10)11(13)14/h1-6,12h,(h,13,14
OPREA1_291089
1-hydroxynaphthalene-2-carboxylic acid
86-48-6
1-naphthol-2-carboxylic acid
1-hydroxy-2-naphthoic acid
C03203 ,
1-hydroxy-2-naphthoic acid, >=97.0%
carboxynaphthol
CHEMBL229299 ,
AKOS001080081
BMSE000689
alpha-hydroxynaphthoic acid
1-hydroxynaphthalene-2-carboxylate
ldha inhibitor, 5
bdbm50219487
H0279
H0796
HMS1719F05
A841684
1hn ,
1-hydroxy-naphthalene-2-carboxylic acid
unii-u8lz3r07l8
ai3-28524
nsc 3717
u8lz3r07l8 ,
einecs 201-674-0
xinafoic acid
BP-12641
FT-0607923
STL373496
FS-3779
1-hydroxy-2-naphthoic acid [mi]
S6364
BBL027444
SCHEMBL25244
1 -hydroxy-2-naphthoic acid
hydroxynaphthalene-2-carboxylic acid
1-hydroxy-2-naphthalene carboxylic acid
DTXSID5058937
.alpha.-hydroxynaphthoic acid
1-hydroxynaphthalenecarboxylic acid-(2)
W-104066
1-hydroxy-2-naphthoicacid
CS-W016819
1-oxidanylnaphthalene-2-carboxylic acid
mfcd00003960
Z56347239
SY007524
HY-W016103
Q27104334
7-naphthol-2-carboxaldehyde
EN300-16632
D70638

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The present study describes the phenanthrene-degrading activity of Sphingomonas paucimobilis 20006FA and its ability to promote the bioavailability of phenanthrene."( Study of the degradation activity and the strategies to promote the bioavailability of phenanthrene by Sphingomonas paucimobilis strain 20006FA.
Berthe-Corti, L; Coppotelli, BM; Del Panno, MT; Dias, RL; Ibarrolaza, A; Morelli, IS, 2010
)
0.36

Dosage Studied

ExcerptRelevanceReference
" Maximum plasma concentrations attained at 1 h after dosing ranged between 35."( The determination in human plasma of 1-hydroxy-2-naphthoic acid following administration of salmeterol xinafoate.
Carey, PF; Chilton, AS; Godward, RE, 1995
)
0.56
" Intranasal administration of low dosage (<1."( Enhanced anti-influenza agents conjugated with anti-inflammatory activity.
Cheng, TJ; Cheng, YS; Fang, JM; Jan, JT; Liu, KC; Wang, SY; Wong, CH; Yang, ST, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
bacterial xenobiotic metaboliteAny bacterial metabolite produced by metabolism of a xenobiotic compound in bacteria.
fungal xenobiotic metaboliteAny fungal metabolite produced by metabolism of a xenobiotic compound in fungi.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
hydroxy monocarboxylic acidAny monocarboxylic acid which also contains a separate (alcoholic or phenolic) hydroxy substituent.
naphthoic acidAn aromatic carboxylic acid that consists of a naphthalene skeleton substituted by one or more carboxy groups.
naphtholsAny hydroxynaphthalene derivative that has a single hydroxy substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Neuraminidase Influenza A virus (A/Wilson-Smith/1933(H1N1))IC50 (µMol)1,000.00000.00000.503510.0000AID612400
NeuraminidaseInfluenza A virus (A/Wilson-Smith/1933(H1N1))IC50 (µMol)100.00000.00040.13430.9930AID716614
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)IC50 (µMol)850.00000.00053.49849.7600AID289410
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (31)

Processvia Protein(s)Taxonomy
lactate metabolic processL-lactate dehydrogenase A chainHomo sapiens (human)
pyruvate metabolic processL-lactate dehydrogenase A chainHomo sapiens (human)
glycolytic processL-lactate dehydrogenase A chainHomo sapiens (human)
lactate metabolic processL-lactate dehydrogenase B chainHomo sapiens (human)
pyruvate metabolic processL-lactate dehydrogenase B chainHomo sapiens (human)
NAD metabolic processL-lactate dehydrogenase B chainHomo sapiens (human)
positive regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of endocytosisTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulum unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of intracellular protein transportTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cellular response to unfolded proteinTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of protein tyrosine kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of receptor catabolic processTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (16)

Processvia Protein(s)Taxonomy
L-lactate dehydrogenase activityL-lactate dehydrogenase A chainHomo sapiens (human)
protein bindingL-lactate dehydrogenase A chainHomo sapiens (human)
identical protein bindingL-lactate dehydrogenase A chainHomo sapiens (human)
cadherin bindingL-lactate dehydrogenase A chainHomo sapiens (human)
L-lactate dehydrogenase activityL-lactate dehydrogenase B chainHomo sapiens (human)
protein bindingL-lactate dehydrogenase B chainHomo sapiens (human)
kinase bindingL-lactate dehydrogenase B chainHomo sapiens (human)
identical protein bindingL-lactate dehydrogenase B chainHomo sapiens (human)
NAD bindingL-lactate dehydrogenase B chainHomo sapiens (human)
RNA bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
zinc ion bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
enzyme bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein phosphatase 2A bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (18)

Processvia Protein(s)Taxonomy
nucleusL-lactate dehydrogenase A chainHomo sapiens (human)
cytosolL-lactate dehydrogenase A chainHomo sapiens (human)
membraneL-lactate dehydrogenase A chainHomo sapiens (human)
extracellular exosomeL-lactate dehydrogenase A chainHomo sapiens (human)
oxidoreductase complexL-lactate dehydrogenase A chainHomo sapiens (human)
mitochondrionL-lactate dehydrogenase A chainHomo sapiens (human)
cytoplasmL-lactate dehydrogenase B chainHomo sapiens (human)
mitochondrial inner membraneL-lactate dehydrogenase B chainHomo sapiens (human)
cytosolL-lactate dehydrogenase B chainHomo sapiens (human)
membraneL-lactate dehydrogenase B chainHomo sapiens (human)
membrane raftL-lactate dehydrogenase B chainHomo sapiens (human)
extracellular exosomeL-lactate dehydrogenase B chainHomo sapiens (human)
oxidoreductase complexL-lactate dehydrogenase B chainHomo sapiens (human)
mitochondrionL-lactate dehydrogenase B chainHomo sapiens (human)
plasma membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial matrixTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial cristaTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
sorting endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID671899Inhibition of human recombinant LDHB (2 to 334 amino acid residue) expressed in Escherichia coli BL21 (DE3) cells after 10 mins by spectrophotometric analysis2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation.
AID612398Octanol-water distribution coefficient, log D of the compound at pH 7.4 at 100 ug/mL2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
Intramolecular ion-pair prodrugs of zanamivir and guanidino-oseltamivir.
AID716598Cytotoxicity against MDCK cells at 100 uM2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Enhanced anti-influenza agents conjugated with anti-inflammatory activity.
AID289410Inhibition of PTP1B2007Bioorganic & medicinal chemistry, Oct-15, Volume: 15, Issue:20
Mono- and disalicylic acid derivatives: PTP1B inhibitors as potential anti-obesity drugs.
AID716613Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) infected in MDCK cells assessed as inhibition of virus induced cytopathic effect2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Enhanced anti-influenza agents conjugated with anti-inflammatory activity.
AID612399Octanol-water distribution coefficient, log D of the compound at pH 6.52011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
Intramolecular ion-pair prodrugs of zanamivir and guanidino-oseltamivir.
AID671897Binding affinity to 6-His-tagged human LDHA (2 to 322 amino acid residue) expressed in Escherichia coli BL21 (DE3) cells by SPR analysis2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation.
AID612401Antiviral activity against influenza A virus A/WSN/1933 (H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
Intramolecular ion-pair prodrugs of zanamivir and guanidino-oseltamivir.
AID127482Ability to bind to monoclonal antibody IgE (Lb4), expressed as association constant (LogKA)1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Comparative molecular field analysis of haptens docked to the multispecific antibody IgE(Lb4)
AID612400Inhibition of influenza A/WSN/1933 (H1N1) virus neuraminidase N1 using MUNANA substrate by fluorimetric assay2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
Intramolecular ion-pair prodrugs of zanamivir and guanidino-oseltamivir.
AID671895Binding affinity to 6-His-tagged human LDHA (2 to 322 amino acid residue) expressed in Escherichia coli BL21 (DE3) cells by NMR analysis in presence of NADH2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation.
AID716614Inhibition of Influenza A virus A/WSN/1933(H1N1)) neuraminidase in the presence of 2'-(4-methyl-umbelliferyl)-alphaD-N-acetylneuraminic acid substrate after 10 mins by fluorometric assay2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Enhanced anti-influenza agents conjugated with anti-inflammatory activity.
AID671898Inhibition of full length human recombinant LDHA expressed in Escherichia coli BL21 (DE3) cells after 10 mins by spectrophotometric analysis2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1799697Enzyme Assay from Article 10.1021/jm201734r: \\Design and synthesis of novel lactate dehydrogenase a inhibitors by fragment-based lead generation.\\2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation.
AID1799695Nuclear Magnetic Resonance (NMR) Assay from Article 10.1021/jm201734r: \\Design and synthesis of novel lactate dehydrogenase a inhibitors by fragment-based lead generation.\\2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (52)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (5.77)18.7374
1990's4 (7.69)18.2507
2000's13 (25.00)29.6817
2010's28 (53.85)24.3611
2020's4 (7.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.87 (24.57)
Research Supply Index4.04 (2.92)
Research Growth Index5.07 (4.65)
Search Engine Demand Index41.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.82%)5.53%
Reviews1 (1.82%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other53 (96.36%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]